Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLK Frequency-Efficacy in Acute Cerebral Ischemic Stroke
NCT02806128Unknown
- Start
- Nov 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Randomised trial of Human urinary kallidinogenase in cerebral infarction. Primary endpoint: National Institute of Health stroke scale at 14 days. Status: unknown.
02
Drugs
Human urinary kallidinogenase
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT02806128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806128.